K. Tomisawa

发表

Binding characteristics of [3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors.

S. Chaki, T. Funakoshi, R. Yoshikawa, 1999, European journal of pharmacology.

In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.

S. Chaki, S. Okuyama, T. Okubo, 1999, European journal of pharmacology.

Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet.

K. Tomisawa, S. Murakami, Y. Kondo-Ohta, 1998, Life sciences.

Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice

S. Okuyama, K. Tomisawa, Y. Imagawa, 1996, Neuropharmacology.

Solubilization and characterization of binding sites for [3H]NE-100, a novel and potent sigma 1 ligand, from guinea pig brain.

S. Chaki, S. Okuyama, A. Nakazato, 1996, Life sciences.

The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5‐hydroxytryptamine2A receptor antagonist, in rats

S. Chaki, S. Okuyama, A. Nakazato, 1997, British journal of pharmacology.

Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700.

K. Tomisawa, S. Uchida, A. Kawashima, 1999, Atherosclerosis.

ACAT inhibitor HL-004 accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL-004.

K. Tomisawa, Y. Yamori, Y. Nara, 1997, Atherosclerosis.

In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats

S. Chaki, T. Funakoshi, R. Yoshikawa, 1999, Neuropharmacology.

Effects of NRA0045, NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain.

S. Chaki, S. Okuyama, K. Tomisawa, 1999, General pharmacology.

Neuroprotective effect of 4'-(4-methylphenyl)-2,2':6',2-terpyridine trihydrochloride, a novel inducer of nerve growth factor.

R. Yoshikawa, S. Okuyama, K. Tomisawa, 1996, Life sciences.

Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists.

S. Chaki, S. Okuyama, T. Okubo, 2000, Bioorganic & medicinal chemistry.

The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.

K. Tomisawa, S. Murakami, Y. Asami, 1996, General pharmacology.

Effect of VA-045 on central noradrenergic neuronal system in rats.

S. Okuyama, K. Tomisawa, K. Kamata, 1996, General pharmacology.

Synthesis and antirheumatic activity of the metabolites of esonarimod.

K. Tomisawa, S. Yokomori, M. Yamashita, 2002, Bioorganic & medicinal chemistry.

Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.

S. Chaki, S. Okuyama, T. Okubo, 1999, The Journal of pharmacology and experimental therapeutics.

Synthesis and structure-activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents.

K. Tomisawa, Toshiya Noguchi, M. Hasegawa, 2003, Bioorganic & medicinal chemistry.

Inhibition of gastric H+, K(+)-ATPase by flavonoids: a structure-activity study.

K. Tomisawa, S. Murakami, M. Muramatsu, 1999, Journal of enzyme inhibition.

Effects of selective dopamine D4 receptor blockers, NRA0160 and L-745,870, on A9 and A10 dopamine neurons in rats.

S. Chaki, S. Okuyama, K. Tomisawa, 1999, Life sciences.

A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.

S. Chaki, T. Funakoshi, R. Yoshikawa, 1999, Life sciences.

In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).

S. Chaki, R. Yoshikawa, S. Okuyama, 1997, The Journal of pharmacology and experimental therapeutics.

Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites

S. Chaki, S. Okuyama, K. Tomisawa, 1998, Neurochemistry International.

Derives de 1,2-dihydro-2-oxoquinoline

S. Chaki, T. Okubo, A. Nakazato, 1998 .

Structure-activity studies of 3-benzoylpropionic acid derivatives suppressing adjuvant arthritis.

K. Tomisawa, S. Hirono, I. Moriguchi, 1992, Chemical & pharmaceutical bulletin.

Immunopharmacological studies of new 3-benzoyl-4-mercaptobutyric acids. Immunomodulating effects.

K. Tomisawa, H. Aihara, S. Otomo, 1988, Arzneimittel-Forschung.

Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats.

K. Tomisawa, T. Suwa, J. Yamaguchi, 1996, Biological & pharmaceutical bulletin.

Studies on antirheumatic agents: 3-benzoylpropionic acid derivatives.

K. Tomisawa, S. Nakaike, K. Kameo, 1988, Chemical & pharmaceutical bulletin.

A practical procedure for the synthesis of esonarimod, (R,S)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid, an antirheumatic agent (part 1).

K. Tomisawa, S. Yokomori, Toshiya Noguchi, 2002 .

Studies on Antirheumatic Agents: 3‐Benzoylpropionic Acid Derivatives.

K. Tomisawa, S. Nakaike, K. Kameo, 1989 .

Prevention of atherosclerotic lesion development in mice by taurine.

K. Tomisawa, S. Murakami, Y. Kondo, 1999, Drugs under experimental and clinical research.

Effect of VA-045, a novel apovincaminic acid derivative, on closed head injury-induced neurological dysfunction in aged rats.

S. Okuyama, K. Tomisawa, K. Kamata, 1997, Neurological research.

INHIBITION OF GASTRIC H+, K+-ATPase BY STUDY FLAVONOIDS: A STRUCTURE-ACTIVITY

K. Tomisawa, S. Murakami, M. Muramatsu, 1999 .

Solubilization and characterization of binding sites for [3H]NE-100, a novel and potent sigma 1 ligand, from guinea pig brain.

S. Chaki, S. Okuyama, A. Nakazato, 1996, Life sciences.

Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106.

S Ogawa, S. Chaki, R. Yoshikawa, 1999, Life sciences.